EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial

Bryony Beal iD, Luke Buizen, Emily K Yeung, Lauren Heath, Lauren Houston, David Z I Cherney, Meg Jardine, Carol Pollock iD, Clare Arnott iD, Sradha S Kotwal, Hiddo J L Heerspink iD, Vlado Perkovic und 1 weitere

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf044 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Bryony Beal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Royal North Shore Hospital, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Insulin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Insulin is a mainstay treatment for diabetes, but its use is associated with weight gain and hypoglycaemia. Data on the effects of sodium–glucose co-transporter 2 (SGLT2) inhibitors on insulin use in people with chronic kidney disease (CKD) are limited.

Methods

We conducted a post hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial. Effects of canagliflozin versus placebo on insulin use (initiation, dose intensification, reduction and discontinuation) in people with CKD and type 2 diabetes were evaluated using Cox regression models. The primary outcome was insulin initiation or a >25% insulin dose intensification (in those not receiving and receiving insulin at baseline, respectively). Effects on kidney, cardiovascular and safety outcomes by baseline insulin use were also assessed.

Results

Among 4401 participants, 2884 (65.5%) were receiving insulin at baseline; these participants were more likely to have lower estimated glomerular filtration rate, higher albuminuria and a longer duration of diabetes (all P < .001). Over a median on-treatment period of 2.0 years, canagliflozin reduced the need for insulin initiation or a >25% dose intensification by 19% compared with placebo {hazard ratio [HR] 0.81 [95% confidence interval (CI) 0.71–0.93]}, irrespective of baseline kidney function or albuminuria (both P-interaction > .10). Sustained insulin dose reductions of >50% were achieved more frequently with canagliflozin than placebo [HR 1.49 (95% CI 1.15–1.91)], although no difference in insulin discontinuation was observed between treatment arms. Effects of canagliflozin on kidney, cardiovascular and safety outcomes were consistent regardless of baseline insulin use (all P-interaction > .05).

Conclusions

In CKD and type 2 diabetes, canagliflozin reduces insulin use with consistent effects regardless of baseline kidney function. This supports the use of canagliflozin in people with CKD, not only for end-organ protection, but also to improve glycaemic control and reduce exposure to insulin and its associated adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicInsulinCanagliflozinHypoglycemic AgentsHumansMaleFemaleMiddle AgedGlomerular Filtration RateDouble-Blind MethodAgedFollow-Up StudiesPrognosisBlood GlucoseSodium-Glucose Transporter 2

Stichwörter der Autor:innen

CKDSGLT2 inhibitorscanagliflozindiabetic kidney diseaseinsulin

Substanzen

Sodium-Glucose Transporter 2 InhibitorsInsulinCanagliflozinHypoglycemic AgentsBlood GlucoseSLC5A2 protein, humanSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Department of Renal Medicine, Royal North Shore Hospital, Sydney, NSW, Australia.
  • George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
  • Department of Nephrology and Transplantation, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
  • Department of Medicine, Division of Nephrology, Toronto General Hospital, Toronto, ON, Canada.
  • NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.

ORCID-Profile: Bryony Beal, Carol Pollock, Clare Arnott, Hiddo J L Heerspink, Brendon L Neuen

Förderung

  • Janssen Research and Development

Zitieren

APA

Beal, B., Buizen, L., Yeung, E. K., Heath, L., Houston, L., Cherney, D. Z. I., Jardine, M., Pollock, C., Arnott, C., Kotwal, S. S., Heerspink, H. J. L., Perkovic, V., & Neuen, B. L. (2025). Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf044

Vancouver

Beal B, Buizen L, Yeung EK, Heath L, Houston L, Cherney DZI, et al. Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf044

BibTeX
@article{Beal2025,
  author = {Beal, Bryony and Buizen, Luke and Yeung, Emily K and Heath, Lauren and Houston, Lauren and Cherney, David Z I and Jardine, Meg and Pollock, Carol and Arnott, Clare and Kotwal, Sradha S and Heerspink, Hiddo J L and Perkovic, Vlado and Neuen, Brendon L},
  title = {Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf044}
}
Kostenlos starten →